Develops biopharmaceutical products for cancer therapy.
Dec 2025Revenue $0.00/yrExpenses $156M/yr
No trendCash runway ≈ 2.2 years from Jun 2026
Figures by year
When will Pliant Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $156M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $156M | −$156M |
| Dec 2024 | $0.00 | $228M | −$228M |
| Dec 2023 | $1.58M | $186M | −$184M |
| Dec 2022 | $9.69M | $137M | −$127M |
| Dec 2021 | $7.57M | $105M | −$97.5M |
| Dec 2020 | $41.8M | $83.5M | −$41.6M |
| Dec 2019 | $57.1M | $58.3M | −$1.23M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.